Rubicon Research's Rs 1,377 crore IPO opens on October 9. The specialty and generics pharmaceutical manufacturer offers shares at Rs 461-485. Grey market premium indicates strong listing expectations. Arihant Capital recommends subscribing due to growth and product pipeline. The company shows a financial turnaround with surging revenue and profit. This IPO offers exposure to a fast-scaling pharma exporter.